The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

IntegriChain, the leading provider of revenue optimization technology and insights for the pharmaceutical industry, today ...

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie ...

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

In 2023, the 340B covered entities purchased $66.3 billion in covered outpatient drugs through the program, compared to $2.4 billion in 2005.

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

Is less transparency and accountability what Ohio needs in healthcare? Some hospital lobbyists think so. They want the Ohio ...

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the ...